A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

BACKGROUND: Pertuzumab is widely used for the treatment of HER2 + breast cancer. But its safety in the real world should be continuously monitored. So, we evaluated the safety of pertuzumab by pharmacovigilance analyze based on related adverse events (AEs) from the FDA Adverse Event Reporting System...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Shu-peng, Yang, Hai-yun, Ouyang, Meng-ling, Cheng, Qian, Shi, Xuan, Sun, Ming-hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642055/
https://www.ncbi.nlm.nih.gov/pubmed/37957717
http://dx.doi.org/10.1186/s40360-023-00702-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642055/
https://www.ncbi.nlm.nih.gov/pubmed/37957717
http://dx.doi.org/10.1186/s40360-023-00702-w

Ejemplares similares